Short Interest in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Drops By 11.9%

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) saw a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 4,090,000 shares, a decrease of 11.9% from the September 15th total of 4,640,000 shares. Based on an average daily volume of 468,500 shares, the days-to-cover ratio is currently 8.7 days.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 136,124 shares of the company’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $25.65, for a total value of $3,491,580.60. Following the sale, the chief executive officer now directly owns 63,012 shares of the company’s stock, valued at approximately $1,616,257.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Mark Ragosa sold 24,248 shares of the stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $24.79, for a total transaction of $601,107.92. Following the sale, the chief financial officer now directly owns 19,253 shares of the company’s stock, valued at $477,281.87. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Sanj K. Patel sold 136,124 shares of the stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $25.65, for a total transaction of $3,491,580.60. Following the sale, the chief executive officer now directly owns 63,012 shares in the company, valued at approximately $1,616,257.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 278,064 shares of company stock valued at $7,165,254. 54.57% of the stock is owned by insiders.

Institutional Trading of Kiniksa Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. CWM LLC raised its holdings in Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $61,000 after acquiring an additional 1,998 shares during the last quarter. nVerses Capital LLC acquired a new stake in Kiniksa Pharmaceuticals in the 3rd quarter valued at about $80,000. Lazard Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals in the 1st quarter valued at about $71,000. Ashton Thomas Private Wealth LLC acquired a new stake in Kiniksa Pharmaceuticals in the 2nd quarter valued at about $100,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Kiniksa Pharmaceuticals by 88.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,708 shares of the company’s stock valued at $152,000 after acquiring an additional 3,611 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Trading Down 2.7 %

Shares of Kiniksa Pharmaceuticals stock opened at $26.32 on Thursday. The firm has a market capitalization of $1.87 billion, a PE ratio of 239.27 and a beta of 0.33. Kiniksa Pharmaceuticals has a twelve month low of $14.12 and a twelve month high of $27.92. The firm’s 50-day moving average price is $25.52 and its 200 day moving average price is $21.86.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. The firm had revenue of $108.30 million for the quarter, compared to analyst estimates of $90.60 million. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. Kiniksa Pharmaceuticals’s quarterly revenue was up 51.5% compared to the same quarter last year. During the same period last year, the company posted ($0.02) EPS. On average, sell-side analysts predict that Kiniksa Pharmaceuticals will post -0.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on KNSA. Jefferies Financial Group began coverage on shares of Kiniksa Pharmaceuticals in a research note on Friday, September 13th. They set a “buy” rating and a $40.00 target price on the stock. Wedbush raised their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $33.60.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.